Showing 321 - 340 results of 26,875 for search '(( 50 ((a decrease) OR (nn decrease)) ) OR ( 50 ((ng decrease) OR (we decrease)) ))', query time: 0.56s Refine Results
  1. 321
  2. 322

    A Minor (<50%) Signet-Ring Cell Component Associated with Poor Prognosis in Colorectal Cancer Patients: A 26-Year Retrospective Study in China by Yinuo Tan (705777)

    Published 2015
    “…<div><p>Background</p><p>We performed a retrospective study to determine the cancer-specific survival of colorectal cancer patients with a component of signet-ring cells or mucin comprising < 50% of the tumor mass.…”
  3. 323

    Neural networks classify states which differ in neuronal activity levels using ensembles of neurons that increase/decrease their activity in each state. by Nicholas A. Frost (10739821)

    Published 2021
    “…As a result, there is an increase (neurons 51:100) or decrease (neurons 1:50) in activity levels in State B compared to State A. …”
  4. 324
  5. 325

    A Yoga Strengthening Program Designed to Minimize the Knee Adduction Moment for Women with Knee Osteoarthritis: A Proof-Of-Principle Cohort Study by Elora C. Brenneman (795723)

    Published 2015
    “…A secondary objective was to determine whether the program could improve mobility and fitness, and decrease peak KAM during gait. …”
  6. 326
  7. 327

    Tacrolimus Decreases Albuminuria in Patients with IgA Nephropathy and Normal Blood Pressure: A Double-Blind Randomized Controlled Trial of Efficacy of Tacrolimus on IgA Nephropathy by Yong-Chul Kim (1637572)

    Published 2013
    “…We randomly assigned patients either to receive tacrolimus or placebo with stratification by using a renin angiotensin system blocker. …”
  8. 328

    DataSheet_1_Hemizygous nonsense variant in the moesin gene (MSN) leads to a new autoimmune phenotype of Immunodeficiency 50.pdf by András L. Kovács (13565251)

    Published 2022
    “…We present a putative new autoimmune phenotype of Immunodeficiency 50 (MIM300988) characterized by antiphospholipid syndrome, Hashimoto’s thyroiditis, leg ulcers, and juvenile tooth loss, associated with W217X mutation of the MSN gene.…”
  9. 329

    Table_2_Move for Life an intervention for inactive adults aged 50 years and older: a cluster randomised feasibility trial.DOCX by Catherine B. Woods (10517765)

    Published 2024
    “…Background<p>Move for Life (MFL) is a theory-informed intervention that was developed to augment established physical activity (PA) programmes and enable inactive adults aged 50 years and older to be more active. …”
  10. 330

    Table_1_Move for Life an intervention for inactive adults aged 50 years and older: a cluster randomised feasibility trial.DOCX by Catherine B. Woods (10517765)

    Published 2024
    “…Background<p>Move for Life (MFL) is a theory-informed intervention that was developed to augment established physical activity (PA) programmes and enable inactive adults aged 50 years and older to be more active. …”
  11. 331
  12. 332
  13. 333
  14. 334
  15. 335
  16. 336

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  17. 337

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  18. 338

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  19. 339

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  20. 340

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”